"From Targets to Translation: Deconvoluting Tumor Vulnerabilities in Drug Development in Hepatobiliary Cancers"

This Center for Evolution and Medicine Seminar features Mitesh J. Borad, M.D., an assistant professor of medicine and director of Phase I Drug Development at Mayo Clinic in Arizona. He obtained his internal medical training at Cedars-Sinai Medical Center and completed his medical oncology fellowship at Tulane University School of Medicine. Prior to joining Mayo Clinic, he spent three years at the Translational Genomics Research Institute as a Genomics Medicine Scholar. He has been serving on the NCI Hepatobiliary Task Force since 2011.

His research and clinical interests are in development of novel treatments for patients with biliary and liver cancers. His team has been engaged in whole genome analysis efforts in cholangiocarcinoma with focus on discovery of novel drug targets and their subsequent implementation in the clinic with the long range goal of providing precision medicine to patients with cholangiocarcinoma.